[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342618-105":59,"doc-detail-342618-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pharmacogenomic-and-epigenomic-approaches-to-untangle-the-enigma-of-il-10-blockade-in-oncology","Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology","","The host immune system status remains an unresolved mystery across malignancies. An immune-compromised state or smart immune-surveillance tactics orchestrated by cancer cells drive invasion and metastasis. Within the tumour-immune microenvironment, cytokine-mediated crosstalk among infiltrating immune cells and cancer cells shapes tumour invasion. Interleukin-10 (IL-10) shows paradoxical effects across cellular and non-cellular components and has been linked to multiple malignancies. This review outlines IL-10’s regulatory role and discusses epigenomic and pharmacogenomic strategies for IL-10 regulation to clarify IL-10 blockade in oncology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacogenomic-and-epigenomic-approaches-to-untangle-the-enigma-of-il-10-blockade-in-oncology/342618/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacogenomic-and-epigenomic-approaches-to-untangle-the-enigma-of-il-10-blockade-in-oncology/342618.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is IL-10 considered a promising immunotherapy target in oncology?","Question",{"text":112,"@type":113},"IL-10 is viewed as promising because blocking IL-10 signalling can improve vaccine-induced T-cell responses and contribute to tumour growth inhibition. However, its complex biology also creates translational challenges.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does the tumour-immune microenvironment play in cancer progression?",{"text":117,"@type":113},"The tumour-immune microenvironment is a complex network of neoplastic cells, stroma, and immune and non-cellular components. Cytokine-mediated interactions can shape aggressiveness, growth rate, and metastatic potential.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review emphasize about IL-10’s effects?",{"text":121,"@type":113},"The review highlights IL-10’s paradoxical, context-dependent actions, including both anti-inflammatory and pro-inflammatory roles, and multiple functions across cellular and non-cellular components within the tumour microenvironment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342618,1790392780,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Expert Reviews in Molecular Medicine  \n[cambridge.org/erm](cambridge.org/erm)  \nReview  \nCite this article: Elemam NM, Mekky RY, Rashid G, Braoudaki M, Youness RA (2024) . Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology. Expert Reviews in Molecular Medicine 26, e1, 1–13. [https://](https://)[ ](https://)[doi.org/10.1017/erm.2023.26](doi.org/10.1017/erm.2023.26)  \nReceived: 19 June 2023  \nRevised: 29 August 2023  \nAccepted: 10 November 2023  \nKeywords:  \nCancer; Cytokines; IL-10; Interleukins; Noncoding RNAs; Pharmacogenomics; Tumourmicroenvironment  \nCorresponding author:  \nRana A. Youness;  \nEmail: [rana.youness21@gmail.com](rana.youness21@gmail.com)  \nCurrent address:  \nBiology and Biochemistry Department, Head of Molecular Genetics Research Team (MGRT), Faculty of Biotechnology, German International University (GIU), Cairo 11835, Egypt  \n© The Author(s), 2024 . Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nPharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology  \nNoha M. Elemam1,2, Radwa Y. Mekky3, Gowhar Rashid4, Maria Braoudaki5 and Rana A. Youness6   \n1Research Instiute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; 2Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; 3Department of Pharmacology and Toxicology, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA University), Cairo 12622, Egypt; 4Amity Medical School, Amity University, Gurugram (Manesar) 122413, Haryana, India; 5Department of Clinical, Pharmaceutical and Biological Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK and 6Biology and Biochemistry Department, Faculty of Biotechnology, German International University, Cairo 11835, Egypt  \nAbstract  \nThe host immune system status remains an unresolved mystery among several malignancies. An immune-compromised state or smart immune-surveillance tactics orchestrated by cancer cells are the primary cause of cancer invasion and metastasis. Taking a closer look at the tumour-immune microenvironment, a complex network and crosstalk between infiltrating immune cells and cancer cells mediated by cytokines, chemokines, exosomal mediators and shed ligands are present. Cytokines such as interleukins can influence all components of the tumour microenvironment (TME), consequently promoting or suppressing tumour invasion based on their secreting source. Interleukin-10 (IL-10) is an interlocked cytokine that has been associated with several types of malignancies and proved to have paradoxical effects. IL-10 has multiple functions on cellular and non-cellular components within the TME. In this review, the authors shed the light on the regulatory role of IL-10 in the TME of several malignant contexts. Moreover, detailed epigenomic and pharmacogenomic approaches for the regulation of IL-10 were presented and discussed.  \nIntroduction  \nThe use of immunotherapy as a novel therapeutic approach in preventing cancer has become widespread (Ref. 1) . Immune checkpoint blockade modalities targeting PD-1 and CTLA-4 provide long-lasting immune responses with established therapeutic benefits for some cancer patients (Refs 2–6) . Although, targeting cytokines is considered a crucial approach in immunotherapy as evidenced in the treatment of solid tumours, such as renal cell carcinoma (RCC) and melanoma, only interferons (IFNs) and IL-2 have been approved by Food and Drug Administration (FDA) for use as cancer therapies (Ref. 7) .  \nIL-10 is considered one of the very promising t","cbCaieDToX3coLTA","https://ap.wps.com/l/cbCaieDToX3coLTA","pdf",525294,13,"English","# Abstract\n# Introduction\n# The tumour microenvironment","[{\"question\":\"Why is IL-10 considered a promising immunotherapy target in oncology?\",\"answer\":\"IL-10 is viewed as promising because blocking IL-10 signalling can improve vaccine-induced T-cell responses and contribute to tumour growth inhibition. However, its complex biology also creates translational challenges.\"},{\"question\":\"What role does the tumour-immune microenvironment play in cancer progression?\",\"answer\":\"The tumour-immune microenvironment is a complex network of neoplastic cells, stroma, and immune and non-cellular components. Cytokine-mediated interactions can shape aggressiveness, growth rate, and metastatic potential.\"},{\"question\":\"What does the review emphasize about IL-10’s effects?\",\"answer\":\"The review highlights IL-10’s paradoxical, context-dependent actions, including both anti-inflammatory and pro-inflammatory roles, and multiple functions across cellular and non-cellular components within the tumour microenvironment.\"}]","Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology | PDF",1790047424,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72407db9d5060e76b0ab5f7051553d55.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44d00c79f27ef0306f3498c2beab700d.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6786c025e2de9a50974ade3341127ea7.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d53559eaa88ce21c74de4e5757dc67fa.webp",980,1385]